Log in
Enquire now
‌

US Patent 11396545 BTLA agonist antibodies and uses thereof

Patent 11396545 was granted and assigned to Eli Lilly and Company on July, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11396545 BTLA agonist antibodies and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.